Nov 12, 2019
Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2019
Oct 30, 2019
Veloxis Increases Outlook for 2019 Based on Continued Strong Performance
Jul 22, 2019
Veloxis Revises Outlook for 2019 Based on Strong Performance
Feb 27, 2019
Veloxis Pharmaceuticals Releases Annual Report for 2018
Jan 02, 2019
Mark Hensley Promoted to Chief Commercial Officer of Veloxis Pharmaceuticals
Nov 14, 2018
Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2018 Highlights
Oct 31, 2018
Ira Duarte Promoted to Chief Financial Officer of Veloxis Pharmaceuticals A/S
Oct 10, 2018
Veloxis to Present at the Jefferies 2018 London Healthcare Conference
Aug 13, 2018
Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2018
Jun 04, 2018
Veloxis Partners with the American Society of Transplant Surgeons to Award First Annual ASTS-Veloxis Fellowship in Transplantation
Apr 20, 2018
FDA Accepts Veloxis's Supplemental New Drug Application for the De Novo Indication for ENVARSUS XR®
Apr 13, 2018
Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting 2018
Apr 03, 2018
Veloxis Appoints Morten Marott as Chief Financial Officer
Mar 28, 2018
Veloxis Announces the Publication of ASERTAA (A Study of Extended Release Tacrolimus in African-Americans), a Phase IIIb study of ENVARSUS XR®
Mar 07, 2018
Veloxis Files with FDA for the De Novo Indication for ENVARSUS XR®
Feb 27, 2018
Veloxis Pharmaceuticals Releases Annual Report for 2017
Feb 14, 2018
Veloxis Secures $60M in Debt Financing
Jun 06, 2017
Veloxis Pharmaceuticals A/S Announces Agreement for Taiba Healthcare to Commercialize Envarsus XR in the Middle East and North Africa Region
Jun 06, 2017
Veloxis Pharmaceuticals A/S and Endo Ventures Limited Jointly Announce Agreement for Paladin Labs Inc. to Commercialize Envarsus XR® in Canada
Jun 06, 2017
Veloxis Pharmaceuticals A/S Announces Agreement with Chiesi Farmaceutici S.p.A. to Commercialize Envarsus XR in China